Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis

Crosbie, Emma J; Zwahlen, Marcel; Kitchener, Henry C; Egger, Matthias; Renehan, Andrew G (2010). Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer epidemiology, biomarkers & prevention, 19(12), pp. 3119-3130. Baltimore, Md.: American Association for Cancer Research AACR 10.1158/1055-9965.EPI-10-0832

[img] Text
Crosbie CancerEpidemiolBiomarkersPrev 2010.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (323kB) | Request a copy

Background: Body mass index (BMI) is a risk factor for endometrial cancer. We quantified the risk and investigated whether the association differed by use of hormone replacement therapy (HRT), menopausal status, and histologic type. Methods: We searched MEDLINE and EMBASE (1966 to December 2009) to identify prospective studies of BMI and incident endometrial cancer. We did random-effects meta-analyses, meta-regressions, and generalized least square regressions for trend estimations assuming linear, and piecewise linear, relationships. Results: Twenty-four studies (17,710 cases) were analyzed; 9 studies contributed to analyses by HRT, menopausal status, or histologic type, all published since 2003. In the linear model, the overall risk ratio (RR) per 5 kg/m2 increase in BMI was 1.60 (95% CI, 1.52–1.68), P < 0.0001. In the piecewise model, RRs compared with a normal BMI were 1.22 (1.19–1.24), 2.09 (1.94–2.26), 4.36 (3.75–5.10), and 9.11 (7.26–11.51) for BMIs of 27, 32, 37, and 42 kg/m2, respectively. The association was stronger in never HRT users than in ever users: RRs were 1.90 (1.57–2.31) and 1.18 (95% CI, 1.06–1.31) with P for interaction ¼ 0.003. In the piecewise model, the RR in never users was 20.70 (8.28–51.84) at BMI 42 kg/m2, compared with never users at normal BMI. The association was not affected by menopausal status (P ¼ 0.34) or histologic type (P ¼ 0.26). Conclusions: HRT use modifies the BMI-endometrial cancer risk association. Impact: These findings support the hypothesis that hyperestrogenia is an important mechanism underlying the BMI-endometrial cancer association, whilst the presence of residual risk in HRT users points to the role of additional systems. Cancer Epidemiol Biomarkers Prev; 19(12); 3119–30.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Social and Preventive Medicine

UniBE Contributor:

Zwahlen, Marcel and Egger, Matthias

ISSN:

1055-9965

Publisher:

American Association for Cancer Research AACR

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:09

Last Modified:

08 Sep 2017 14:29

Publisher DOI:

10.1158/1055-9965.EPI-10-0832

PubMed ID:

21030602

Web of Science ID:

000285285900013

BORIS DOI:

10.7892/boris.1137

URI:

https://boris.unibe.ch/id/eprint/1137 (FactScience: 201943)

Actions (login required)

Edit item Edit item
Provide Feedback